Group 1 - The core viewpoint of the articles highlights the robust performance growth of the companies, with 巨子生物 achieving a revenue of RMB 3.11 billion, a year-on-year increase of 22.5%, and a net profit of RMB 1.18 billion, up 20.6% [1] - The revenue growth for 巨子生物 is attributed to deepening online and offline channels, enhancing operational capabilities, consolidating star products, upgrading core products, and strengthening brand marketing [1] - 可丽金 reported a sales revenue of RMB 502.7 million, a 26.9% increase compared to the same period in 2024, accounting for 16.1% of total revenue, driven by online channel expansion and successful upgrades of star products [2] Group 2 - 巨子生物 invested RMB 41 million in R&D, representing 1.3% of its revenue, with over 140 projects under research and 186 patents authorized or applied for [1] - 可丽金's products are available in approximately 1,700 public hospitals, 3,000 private hospitals and clinics, over 130,000 chain pharmacies, and around 6,000 CS/KA stores, utilizing various online platforms for sales and promotion [2] - Looking ahead to the second half of 2025, 可丽金 plans to strengthen its technological research and brand communication, ensuring sustainable and high-quality operational capabilities [2]